Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
40832239 (PubMed )
Supplement: media-1.pdf
SMARCA2 Deficiency While Preserving SMARCA4 in Lung Adenocarcinoma Combined with Abnormal β-Catenin Expression.
Dai X et al.
Cancer Management and Research, 2025
Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform.
Dorighi KM et al.
Cell Reports, 2024
Next-Generation Sequencing Analysis of Mutations in Circulating Tumor DNA from the Plasma of Patients with Head-Neck Cancer Undergoing Chemo-Radiotherapy Using a Pan-Cancer Cell-Free Assay.
Koukourakis MI et al.
Current Oncology (toronto, Ont.), 2023
Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.
Kahraman Çetin N et al.
Balkan Medical Journal, 2021
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y et al.
Cancer Research and Treatment, 2021
Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.
Stenman A et al.
Endocrine Pathology, 2020
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
Craig DJ et al.
Bmc Cancer, 2019
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
31668570 (PubMed )
Supplement: mmc4.xlsx › Sheet1
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Zhang G et al.
Annals of Translational Medicine, 2019
Comprehensive identification of long noncoding RNAs in colorectal cancer.
James de Bony E et al.
Oncotarget, 2018
29963224 (PubMed )
Supplement: oncotarget-09-27605-s005.xlsx › Sheet1
The effects of mutational processes and selection on driver mutations across cancer types.
Temko D et al.
Nature Communications, 2018
29748584 (PubMed )
Supplement: 41467_2018_4208_MOESM1_ESM.pdf
Targeting mutant p53 for efficient cancer therapy.
Bykov VJN et al.
Nature Reviews. Cancer, 2018
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM et al.
International Journal of Cancer, 2016
26991344 (PubMed )
Supplement: IJC-139-647-s003.xls › Suppl_Tbl_2
Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
Xiu J et al.
Oncotarget, 2016
26933808 (PubMed )
Supplement: oncotarget-07-21556-s001.pdf
Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines.
Dietlein F et al.
Human Molecular Genetics, 2014
Select a paper to view details